Sign in
Taking people in South KoreaNo phase

Keeping Versus Removing Dental Implants in Jaw Bone Osteonecrosis

Compares keeping or removing dental implants in adults with medication-related jaw bone osteonecrosis.

Key facts

Who runs it
Kyunghee University Dental Hospital
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Comparing Implant Retention Versus Removal for MRONJ at Implant Sites
Status
Recruiting
People taking part
50 people, planned
Started
6 Apr 2026
Expected to end
Jun 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Implant Retention Surgery
  • Implant Removal Sugery
Record updated
10 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with medication-related osteonecrosis of the jaw (MRONJ) at a dental implant site. The implant is firm, with some bone loss around it.

Age
20 years or older
Sex
All sexes can join
Disease stage
MRONJ at AAOMS stage 0, 1, or 2, with at least one dental implant in the affected area. X-rays show bone loss of 20% or more and less than 60% of the implant length. The implant is not loose.
Earlier treatment
The person has been treated with antiresorptive medicines (for example bisphosphonates or denosumab) and/or selective estrogen receptor modulators (SERMs).

Main reasons for not taking part

  • Past radiotherapy to the head and neck
  • Cancer that has spread, multiple myeloma, or Paget's disease of the jaw
  • Current anti-angiogenic or immunomodulatory cancer medicines
  • Uncontrolled illness that could affect surgery or healing
  • Bone loss around the implant below 20% or 60% and above

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients diagnosed with medication-related osteonecrosis of the jaw (MRONJ) (AAOMS stage 0, 1, or 2) who have been treated with antiresorptive agents (e.g., bisphosphonates or denosumab) and/or selective estrogen receptor modulators (SERMs)
  • Presence of an MRONJ lesion involving at least one dental implant at the affected site
  • Radiographic peri-implant bone loss between ≥20% and <60% of the implant length at the most severe area on baseline imaging
  • No implant mobility
  • Able and willing to provide written informed consent after receiving an adequate explanation of the study purpose and procedures

Who cannot take part

  • Current treatment with anti-angiogenic agents (e.g., bevacizumab, ranibizumab, lenalidomide, sunitinib) or immunomodulatory agents (e.g., methotrexate) for cancer therapy
  • Peri-implant bone loss outside the predefined range (<20% or ≥60%) on preoperative imaging or intraoperative assessment
  • History of radiotherapy to the head and neck region
  • Presence of metastatic disease or bone diseases such as multiple myeloma or Paget's disease of the jaw
  • Uncontrolled systemic disease that may contraindicate surgery or impair healing (e.g., uncontrolled diabetes, recent chemotherapy, severe immunosuppression)
  • Refusal of treatment or follow-up, withdrawal of consent, or inability to comply with study procedures

Where in South Korea

  • Kyung Hee University Dental HospitalSeoul, South KoreaContact: Junghye Hwang, DDS, MSTaking people

About the trial

What the trial wants to find out

Medication-related osteonecrosis of the jaw (MRONJ) is a condition that can occur in patients who take medications such as antiresorptive drugs for osteoporosis and other bone-related systemic diseases. Although the overall risk is relatively low, the number of affected patients is increasing as the population ages and dental implants are increasingly used to restore chewing function. When MRONJ develops at an implant site, deciding whether to keep or remove the implant becomes a difficult clinical problem.

Read full original descriptionShow less

Current treatment recommendations for MRONJ are mainly based on disease stage. However, in situations where only part of the bone around an implant is affected, and the entire implant surface is not involved, there are no clear, evidence-based criteria to guide the decision between implant retention and implant removal. Some clinicians recommend removing all implants associated with necrotic bone to reduce the risk of recurrence. Others attempt to preserve implants that appear less severely affected. Implant retention may carry a risk of delayed healing or recurrence, whereas implant removal may cause additional surgical trauma that could potentially worsen the condition. Therefore, more objective criteria are needed to support clinical decision-making.

In peri-implantitis, another disease affecting the tissues around implants, the amount of bone loss observed on radiographs is often used as a reference for treatment decisions. Traditionally, implant removal has been considered when bone loss reaches approximately 50-60% of the implant length. When bone loss is less extensive, treatment aimed at preserving the implant may be attempted. However, it is unknown whether a similar bone loss threshold applies to patients with implant-related MRONJ.

The purpose of this prospective study is to evaluate whether the extent of peri-implant bone loss-particularly within the range of 20% to 60% of the implant length-can serve as a practical reference for deciding whether to retain or remove an implant in patients with implant-related MRONJ. By comparing clinical outcomes between implant retention and implant removal within this range of bone loss, this study aims to determine whether a bone-loss-based criterion can support treatment decisions.

The primary outcome of the study is complete mucosal healing at 6 months after treatment. Additional outcomes, including radiographic changes assessed by cone-beam computed tomography (CBCT) and recurrence of MRONJ-related clinical signs, will also be evaluated during the 1-year follow-up period after treatment initiation. CBCT imaging will be performed at 6 and 12 months after treatment to assess bone changes over time. Approximately 50 patients will be enrolled in this single-center prospective study. The findings are expected to provide structured clinical data to guide implant management decisions in patients with implant-related MRONJ.

The 2 groups in the trial

  • Implant RetentionExisting treatment, for comparison

    Participants receive a treatment strategy aimed at preserving the affected implant when feasible. The approach includes surgical management of necrotic bone and decontamination of the exposed implant surface, with the goal of maintaining implant stability and achieving mucosal healing.

    Treatment: Implant Retention Surgery

  • Implant RemovalExisting treatment, for comparison

    Participants receive a treatment strategy involving surgical removal of the affected implant together with resection of necrotic bone to eliminate the source of infection and promote healing.

    Treatment: Implant Removal Sugery

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Implant Retention Versus Removal for MRONJ at Implant Sites: A Prospective Study
Plain-language title
Keeping Versus Removing Dental Implants in Jaw Bone OsteonecrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 August 2026